2m 2m 2m 2m 2m 2m 2m
Corcept Therapeu (CORT)
NASDAQ
$81.29+$1.44 (+1.80%)
Price as of Jun 23, 2026 7:58 PM EDT- $8.6BMarket Cap
- 7.31%1-Year Change
- BiotechnologyIndustry
Corcept Therapeu (CORT)
$81.29+$1.44 (+1.80%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 761.4M +12.79% | 675.0M +39.94% | 482.4M +20.04% | 401.9M +9.80% | |
Cost of Revenue | 13.0M +19.25% | 10.9M +67.91% | 6.5M +20.35% | 5.4M +1.97% | |
Gross Profit | 748.4M +12.69% | 664.2M +39.56% | 475.9M +20.03% | 396.5M +9.92% | |
Sales and Marketing Expense | 448.7M +60.08% | 280.3M +52.13% | 184.3M +20.55% | 152.8M +24.92% | |
Research and Development Expense | -254.9M +3.25% | -246.9M +33.92% | -184.4M +40.74% | -131.0M +15.04% | |
Depreciation and Amortization Expense | 1.1M +44.53% | 795,000 +70.97% | 465,000 -40.54% | 782,000 -27.05% | |
Total Operating Expenses | 716.6M +33.18% | 538.1M +43.45% | 375.1M +29.69% | 289.2M +19.76% | |
Operating Profit | 44.8M -67.29% | 137.0M +27.66% | 107.3M -4.75% | 112.6M -9.51% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 21.7M -11.72% | 24.5M +42.07% | 17.3M N/A | N/A N/A | |
Income before Taxes | 66.5M -58.84% | 161.5M +29.65% | 124.6M +7.20% | 116.2M -7.05% | |
Income Taxes | -33.2M -263.62% | 20.3M +10.14% | 18.4M +24.67% | 14.8M +18.24% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 99.7M -29.43% | 141.2M +33.04% | 106.1M +4.66% | 101.4M -9.86% | |
Net Income from Continuing Operations Applicable to Common | 98.2M -29.74% | 139.7M +32.45% | 105.5M +4.15% | 101.3M -18.97% | |
Basic EPS and Net Income | 0.95 -29.63% | 1.35 +32.35% | 1.02 +7.37% | 0.95 -2.06% | |
Diluted EPS and Net Income | 0.82 -33.33% | 1.23 +30.85% | 0.94 +8.05% | 0.87 -2.25% | |
Basic Weighted Average Shares | 103.9M +0.61% | 103.2M -0.32% | 103.6M -3.02% | 106.8M -7.67% | |
Diluted Weighted Average Shares | 120.0M +5.73% | 113.5M +1.56% | 111.7M -3.64% | 116.0M -7.94% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 120.5M -5.62% | 127.7M -5.82% | 135.6M +104.36% | 66.3M -14.54% | |
Short-Term Investments | 251.7M -1.57% | 255.7M +9.88% | 232.7M -36.31% | 365.3M +150.38% | |
Cash and Cash Equivalents and Short-Term Investments | 372.2M -2.92% | 383.3M +4.10% | 368.2M -14.70% | 431.7M +93.11% | |
Total Current Assets | 485.5M +2.94% | 471.6M +2.83% | 458.6M -8.14% | 499.3M +87.36% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | 3.7M +26.74% | |
Property and Plant and Equipment and Net | 1.9M -29.71% | 2.7M +1,278.97% | 195,000 -69.19% | 633,000 -36.83% | |
Total Long-Term Assets | 5.2M -22.04% | 6.6M +1.05% | 6.5M +29.32% | 5.1M +64.06% | |
Total Assets | 836.7M -0.46% | 840.6M +35.24% | 621.5M +6.53% | 583.4M +37.68% | |
Income Taxes Payable | 15.2M +7.75% | 14.1M +36.64% | 10.3M +13.30% | 9.1M +2,124.21% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 166.1M +17.98% | 140.8M +34.70% | 104.5M +44.16% | 72.5M +52.48% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 5.0M -17.75% | 6.1M +3,944.37% | 151,000 -86.79% | 1.1M N/A | |
Total Liabilities | 188.8M +17.32% | 161.0M +40.20% | 114.8M +40.72% | 81.6M +70.15% | |
Retained Earnings | 643.4M +18.33% | 543.7M +35.08% | 402.5M +35.81% | 296.4M +52.02% | |
Total Stockholders Equity | 647.8M -4.68% | 679.6M +34.12% | 506.7M +0.97% | 501.8M +33.54% | |
Total Shares Outstanding | 106.0M +0.81% | 105.1M +1.65% | 103.4M -4.11% | 107.8M +1.79% | |
Cash Flow | |||||
Cash from Operating Activities | 142.0M -28.31% | 198.1M +55.91% | 127.0M +5.58% | 120.3M -28.33% | |
Capital Expenditures | 211,000 -90.29% | 2.2M +1,462.59% | 139,000 -66.34% | 413,000 -11.94% | |
Cash from Investing Activities | 69.8M +139.28% | -177.6M -295.37% | 90.9M +179.51% | -114.3M -183.99% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -220.4M +677.33% | -28.3M -80.94% | -148.7M +760.47% | -17.3M -94.29% | |
Financials Ratio | |||||
Gross Margin | 98.30% -0.09% | 98.39% -0.27% | 98.66% -0.004% | 98.66% +0.10% | |
Operating Margin | 5.88% -71.00% | 20.29% -8.78% | 22.24% -20.65% | 28.03% -17.59% | |
Return on Assets | 11.88% -38.48% | 19.32% +9.64% | 17.62% -12.52% | 20.14% -10.91% | |
Return on Equity | 15.01% -36.93% | 23.81% +13.11% | 21.05% -8.93% | 23.11% -7.65% | |
Revenue Growth | 12.79% -67.97% | 39.94% +99.34% | 20.04% +104.37% | 9.80% +186.63% | |
Current Ratio | 2.92 -12.75% | 3.35 -23.67% | 4.39 -36.28% | 6.89 +22.88% | |
Cash Ratio | 0.73 -20.00% | 0.91 -30.08% | 1.30 +41.76% | 0.92 -43.95% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow